Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304464 | 0.83 | KIF11 (0.35) | KIF11LTA4HNPC1RAB9AL3MBTL1 | |
| SCHEMBL12099900 | 0.81 | PKM (0.39) | PKMNPC1RAB9AL3MBTL1 | |
| SCHEMBL1078041 | 0.65 | ALDH1A1 (0.43) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL1304403 | 0.65 | MAPT (0.36) | POLBNPC1RAB9A | |
| SCHEMBL5309684 | 0.63 | ALPL (0.44) | POLBNPC1RAB9AL3MBTL1 | |
| SCHEMBL12468595 | 0.63 | PARP10 (0.39) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL5367643 | 0.60 | SSTR4 (0.51) | POLBNPC1RAB9AL3MBTL1 | |
| SCHEMBL3249158 | 0.59 | RECQL (0.40) | L3MBTL1 | |
| SCHEMBL6544667 | 0.59 | ALDH1A1 (0.41) | PKMNPC1RAB9A | |
| SCHEMBL1835145 | 0.59 | ALPI (0.55) | KIF11PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| US-6605642-B2 | Administering specified compounds which are derivatives of phenoxyisobutyric acids and of benzoic acid including aryl and heterocyclic ureido derivatives and aryl and heterocyclic carboxamido derivatives; treating aging, arthritis, diabetes | CITY OF HOPE | 2003-08-12 | — | — | US | claimed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | disclosed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |